InVivo Therapeutics Appoints Richard Toselli, M.D. as Chief Medical Officer
July 10 2017 - 8:00AM
Business Wire
InVivo Therapeutics Holdings Corp. (NVIV) today
announced the appointment of Richard Toselli, M.D., as Chief
Medical Officer, effective July 5, 2017. Dr. Toselli, a
fellowship-trained spinal neurosurgeon, will assume all
responsibilities related to the company’s clinical and regulatory
strategy.
Prior to joining InVivo, Dr. Toselli served as Chief Medical
Officer for Cochlear Limited. In that role, he was responsible for
global clinical, regulatory, and medical affairs teams reporting to
the CEO. Prior to that, Dr. Toselli served five years at Sanofi in
various levels of increasing responsibility, including Vice
President of Global Medical Affairs – Immunology and Inflammation,
Biologics Division; Vice President of Global Medical Affairs and
Head of the Biosurgery Discovery Performance Unit; and Vice
President of Global Medical Affairs, Biosurgery. Before his time at
Sanofi, he served as Chief Medical/Technology Officer for Covidien
Surgical, and earlier held various roles at DePuy Spine including
Director of Medical Affairs, Worldwide Vice President of Research
and Development, and Worldwide Vice President of Clinical Evidence
and External Relations. He subsequently held the position of Vice
President of Evidence-Based Medicine at Johnson & Johnson for
the device sector.
Mark Perrin, InVivo’s Chief Executive Officer and Chairman,
said, “We are pleased to welcome Rich to the InVivo team during
this pivotal moment in the company’s history. His deep industry
experience paired with his medical training as a spine trauma
neurosurgeon make him an invaluable asset as we look to finish
enrollment of our pivotal probable benefit study and file for
marketing approval.”
Dr. Toselli’s previous academic positions include Assistant
Professor at Brown University, Associate Professor, Director of
Spine Center, and Associate Chief of Staff at the University of
North Carolina (UNC), and Associate Professor at the University of
Vermont. He holds a bachelor of arts from Providence College, his
medical degree from Brown University, and a masters of business
administration from the UNC’s Kenan-Flagler Business School. Dr.
Toselli is a board-certified neurological surgeon.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and
clinical-stage biomaterials and biotechnology company with a focus
on treatment of spinal cord injuries. The company was founded in
2005 with proprietary technology co-invented by Robert Langer,
Sc.D., Professor at Massachusetts Institute of Technology, and
Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital
and who now is affiliated with Massachusetts General Hospital. In
2011, the company earned the David S. Apple Award from the American
Spinal Injury Association for its outstanding contribution to
spinal cord injury medicine. In 2015, the company’s investigational
Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine
Device Award. The publicly-traded company is headquartered in
Cambridge, MA. For more details, visit
www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
within the meaning of the federal securities laws. These statements
can be identified by words such as "believe," "anticipate,"
"intend," "estimate," "will," "may," "should," "expect," “designed
to,” “potentially,” and similar expressions, and include statements
regarding the safety and effectiveness of the Neuro-Spinal
Scaffold, the progress of the clinical program and the timing of
the completion of enrollment in the INSPIRE Study and of the filing
of an application for marketing approval. Any forward-looking
statements contained herein are based on current expectations, and
are subject to a number of risks and uncertainties. Factors that
could cause actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the company’s ability to successfully
open additional clinical sites for enrollment and to enroll
additional patients; the timing of the Institutional Review Board
process; the company’s ability to commercialize its products; the
company’s ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the company’s
products and technology in connection with the treatment of spinal
cord injuries; the availability of substantial additional funding
for the company to continue its operations and to conduct research
and development, clinical studies and future product
commercialization; and other risks associated with the company’s
business, research, product development, regulatory approval,
marketing and distribution plans and strategies identified and
described in more detail in the company’s Quarterly Report of the
three months ended March 31, 2017, and its other filings with the
SEC, including the company’s Form 10-Qs and current reports on Form
8-K. The company does not undertake to update these forward-looking
statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170710005414/en/
InVivo TherapeuticsHeather Hamel, 617-863-5530Investor
RelationsInvestor-relations@invivotherapeutics.com
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Apr 2024 to May 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From May 2023 to May 2024